International Symposium on
CHRONIC LYMPHOCYTIC LEUKEMIA:
ADVANCES IN PATHOGENESIS AND
TREATMENT
Venice, March 8th-10th, 2018

Organised by:
Centro di Riferimento Oncologico, Aviano (PN)

Promoted by:
Fondazione Internazionale Menarini

PRELIMINARY PROGRAMME

Sala del Ridotto – Hotel Monaco & Grand Canal
Venice
The chronic lymphocytic leukemia (CLL) is the most frequent leukemia in western world, and its incidence is significantly higher in elderly. Although in the past changes in the management of CLL patients occurred very slowly with few relevant findings in CLL biology, in the last 1-2 decades, we are witnessing an unprecedented burst of new discoveries that has rapidly transformed a relatively homogeneous and lethal disease into an unexpectedly heterogeneous one that can be often controlled for long periods thanks to an armamentarium of novel well-tolerated biologic drugs.

Given this scenario, a recapitulation of the several changes rapidly occurring in the fields of CLL pathogenesis, classification and risk stratification, as well as in the management of CLL patients has been though more than appropriate nowadays.

To do so, this meeting will encompass in the same context both “basic” topics (role of genetics, BCR and microenvironment interactions in CLL pathogenesis) and more “clinical” aspects (prognostic and predictive factors, role of chemo-immunotherapy and of target therapies, as well as of salvage therapies), all discussed by well-known CLL experts to provide an updated state-of-the-art on CLL useful for students, hematologists, practitioners and researchers.

Along with the Scientific Directorate of the Aviano Cancer Center, the meeting organizers and supporters, I look forward to welcoming you in Venice in March 2018

President of the Meeting
Valter Gattei
Clinical and Experimental Onco-Hematology Unit
Centro di Riferimento Oncologico, I.R.C.C.S.
Aviano, Italy
With the patronage of

Società Italiana di Ematologia Sperimentale (SIES)

Università degli Studi di Udine

Università degli Studi di Trieste

Associazione Italiana per la Ricerca sul Cancro (AIRC) – TO BE CONFIRMED
Società Italiana di Ematologia (SIE) – TO BE CONFIRMED
International Society Cell Therapy – TO BE CONFIRMED

President of the Meeting
Valter Gattei

Promoted by:
Fondazione Internazionale Menarini
Centro Direzionale Milanofiori
20089 Rozzano (Milan, Italy)
Edificio L - Strada 6
Phone: +39 02 55308110
Fax: +39 02 55305739
E-mail: milan@fondazione-menarini.it
Website: www.fondazione-menarini.it

Organising Secretariat and CME Provider
AVEC S.r.l. - Incentive Paintings - Angela Volpe
Via Lavoratori Autobianchi, 1 - c/o Polo Tecnologico Brianza - Edificio 9 - Ufficio 14
I-20832 Desio (MB), Italy
Phone: +39 0362 581579 – Fax: +39 0362 1860074
E-mail: angela.volpe@avec-eventi.com
Thursday, March 8th, 2018 – Afternoon

01.00 p.m. – 02.00 p.m.  Welcome lunch

02.00 p.m. – 02.15 p.m.  Valter Gattei (Aviano, IT), Paolo De Paoli (Aviano, IT)
Introduction

02.15 p.m. – 02.30 p.m.  Alessandro Casini (Florence, IT)
Welcome to participants

Opening Lecture
Chairperson     Paolo De Paoli (Aviano, IT)

02.30 p.m. – 03.30 p.m.  Carlo M. Croce (Columbus, US)
The role of microRNA in CLL pathogenesis

Session I: Microenvironmental interactions: the role of BCR
Chairpersons     Tanjia N. Hartmann (Salzburg, AT), Livio Trentin (Padua, IT)

03.30 p.m. – 04.00 p.m.  Francesco Forconi (Southampton, UK)
BCR and CLL cell survival

04.00 p.m. – 04.30 p.m.  Kostas Stamatopoulos (Tessaloniki, GR)
Revelations from BCR structures

04.30 p.m. – 05.00 p.m.  Coffee break

05.00 p.m. – 05.30 p.m.  Dimitar G. Efremov (Trieste, IT)
BCR signaling: the lesson of murine models

05.30 p.m. – 06.00 p.m.  Hassan Jumaa (Ulm, DE)
Antigen-independent BCR autonomous signaling

06.00 p.m. – 06.30 p.m.  General discussion
Friday, March 9th, 2018 – Morning

Session II: Microenvironmental interactions beyond BCR

Chairpersons
Massimo Massaia (Turin, IT), Roberto Marasca (Modena, IT)

09.00 a.m. – 09.30 a.m.
Jan Burger (Houston, US)
The role of nurse-like cells

09.30 a.m. – 10.00 a.m.
Antonella Zucchetto (Aviano, IT)
The role of the VLA-4 integrin

10.00 a.m. – 10.30 a.m.
Silvia Deaglio (Turin, IT)
Mechanisms of immunosuppression in the Chronic Lymphocytic Leukemia niche

Chairperson
Valter Gattei (Aviano, IT)

10.30 a.m. – 11.15 a.m.
John Gribben (London, UK)
Keynote Lecture: The immune synapses in CLL

11.15 a.m. – 11.45 a.m.
Coffee break

Session III: The genetic landscape of CLL

Chairpersons
Francesco Bertoni (Bellinzona, CH), Francesco Di Raimondo (Catania, IT)

11.45 a.m. – 12.15 p.m.
Elias Campo (Barcelona, ES)
Recurrent gene mutations in CLL

12.15 p.m. – 12.45 p.m.
Davide Rossi (Bellinzona, CH)
NOTCH1 and SF3B1 mutations: physiopathology and clinical implications

12.45 p.m. – 01.15 p.m.
Richard Rosenquist (Uppsala, SE)
Novel/rare mutations: physiopathology and clinical implications

01.15 p.m. – 02.15 p.m.
Buffet lunch
Friday, March 9th, 2018 – Afternoon

Session IV: Prognostic and predictive factors in CLL

Chairpersons  
Giovanni Del Poeta (Rome, IT), Marco Montillo (Milan, IT)

02.15 p.m. – 02.45 p.m.  
Neil E. Kay (Rochester, US)  
Update on MBL: Biologic and Clinical Advances

02.45 p.m. – 03.15 p.m.  
Gianluca Gaidano (Novara, IT)  
Novel and old prognosticators

03.15 p.m. – 03.45 p.m.  
Paolo Ghia (Milan, IT)  
MRD as the new frontier of CLL management

Chairperson  
Giovanni Pizzolo (Verona, IT)

03.45 p.m. – 04.30 p.m.  
Federico Caligaris-Cappio (Milan, IT)  
Keynote Lecture: The CLL ecosystem and what it means for novel treatment approaches

04.30 p.m. – 05.00 p.m.  
Coffee break

Session V: From chemo-immunotherapy to target therapies

Chairpersons  
Gabriele Pozzato (Trieste, IT), Luca Laurenti (Rome, IT)

05.00 p.m. – 05.30 p.m.  
Barbara Eichorst (Koln, DE)  
Chemo-immunotherapeutic approaches today

05.30 p.m. – 06.00 p.m.  
Adrian Wiestner (Bethesda, US)  
BTK/BCR inhibitors in CLL

06.00 p.m. – 06.30 p.m.  
William G. Wierda (Houston, US)  
BCL-2 inhibitors in CLL
Saturday, March 10th, 2018 – Morning

Session VI: From target therapies to salvage therapies

Chairpersons: Michele Spina (Aviano, IT), Francesco Zaja (Udine, IT)

09.00 a.m. – 09.30 a.m. Alessandra Ferrajoli (Houston, US)
Comorbidities and other cancers in patients with CLL

09.30 a.m. – 10.00 a.m. Robin Foà (Rome, IT)
New mechanism-based drugs for all patients? Still a role for chemo-immunotherapy?

10.00 a.m. – 10.15 a.m. Discussion

10.15 a.m. – 10.45 a.m. Coffee break

10.45 a.m. – 11.15 a.m. Peter Dreger (Heidelberg, DE)
Allo-transplant in CLL

11.15 a.m. – 11.45 a.m. Elizabeth Shpall (Houston, US)
CAR-T in CLL

11.45 a.m. – 12.00 p.m. Discussion

Closing Lecture

Chairperson: Valter Gattei (Aviano, IT)
12.00 p.m. – 01.00 p.m. Riccardo Dalla-Favera (New York, US)
Advances on the molecular pathogenesis of CLL

01.00 p.m. – 02.00 p.m. Buffet lunch

Session VII: Take-home-messages and future perspectives

Chairpersons: Gianluca Gaidano (Novara, IT), Dimitar G. Efremov (Trieste, IT)
02.00 p.m. – 02.30 p.m.  Nicholas Chiorazzi (Manhasset, US)
BCR/microenvironment in CLL: future perspective

02.30 p.m. – 03.00 p.m.  Catherine Wu (Boston, US)
Genetics in CLL: future perspectives

03.00 p.m. – 03.30 p.m.  Emili Montserrat (Barcelona, SP)
Clinical management of CLL: future perspective

03.30 p.m. – 04.30 p.m.  Closing remarks
GENERAL INFORMATION

Meeting venue
Sala del Ridotto – Hotel Monaco & Grand Canal - Piazza San Marco, 1332, 30124 Venice

Registration hours:
Thursday, March 8th: 12.00 p.m. to 06.30 p.m.
Friday, March 9th: 08.00 a.m. to 06.30 p.m.
Saturday, March 10th: 08.00 a.m. to 04.30 p.m.

Official language
English. Simultaneous translation will not be provided.

Registrations
No registration fee is required to attend the Conference. Please return the registration form to:
AVEC S.r.l. - Incentive Paintings - Angela Volpe
Via Lavoratori Autobianchi, 1 - c/o Polo Tecnologico Brianza - Edificio 9 - Ufficio 14
I-20832 Desio (MB, Italy)
Phone: +39 0362 581579 – Fax: +39 0362 1860074
E-mail: angela.volpe@avec-eventi.com / info@avec-eventi.com

Congress website
www.chroniclymphocyticleukemia-cro2018.com

Accreditation
An application has been made for Continuing Medical Education (CME) accreditation of this event by Avec to the following institutions:
- European Accreditation Council for Continuing Medical Education (EACCME)
- Italian Accreditation for Continuing Medical Education (ECM)

Continuing Medical Education (CME) Credits
Each participant should claim only those hours of credit that have actually been spent in the educational activity.

Technical facilities
A Slide Center with PCs (Windows and Macintosh operating systems) will be available for Speakers to preview and finalize their presentations. Speakers are kindly requested to submit their presentations on USB flash drive to the Slide Center technicians at least one hour before their talks.
Slide Centre opening hours:
Thursday, March 8th: 12.00 p.m. to 06.30 p.m.
Friday, March 9th: 08.00 a.m. to 06.30 p.m.
Saturday, March 10th: 08.00 a.m. to 04.30 p.m.

Lunch and coffee breaks
Lunch and coffee breaks will be provided on the conference premises.

Abstract book
Participants will receive the Abstract book at the Conference.

Attendance certificate
The attendance certificate will be provided on-site upon request at the Registration Desk.
Registration form
International Symposium on
CHRONIC LYMPHOCYTIC LEUKEMIA: ADVANCES IN PATHOGENESIS AND TREATMENT
Venice (Italy), March 8th-10th, 2018

Promoted by:

[Logo]

[ ] Physician [ ] Postgraduate

<table>
<thead>
<tr>
<th>Surname</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Title</th>
<th>Professional Area</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Address</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>City</th>
<th>Postcode</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Telephone</th>
<th>Mobile</th>
<th>Fax</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E-mail</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

No registration fee is required to attend the conference. Please return the registration form to:

AVEC S.r.l. - Incentive Paintings - Angela Volpe
Via Lavoratori Autobianchi, 1 - c/o Polo Tecnologico Brianza - Edificio 9 - Ufficio 14
I-20832 Desio (MB), Italy
Tel.: +39 0362 581579 – Fax: +39 0362 1860074
E-mail: info@avec-eventi.com

<table>
<thead>
<tr>
<th>Date</th>
<th>Signature</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
RE: Informative note pursuant to art. 13 of Legislative Decree 196/2003

Dear Client, this is to inform you that the processing of your personal data will be carried out in our company in full compliance with Law 2003. As established by this law, the processing will be based on the principles of correctness, lawfulness and transparency in order to protect your confidentiality and rights.

1) Pursuant to art. 13 we inform you that the data collected will be used for the following purposes:

- a. Organization of events, travel incentives, congresses and conventions: performance of bureaucratic procedures, reservation of tickets for transport, hotels, tourist services; organisational logistics, etc., and/or performance of accreditation procedures (ECM);
- b. Taxation and accounting obligations;
- c. Operational and managerial requirements;
- d. Possible forwarding of informative and promotional material relating to our sector in printed form or electronically.

2) For data required to fulfil obligations envisaged by law, regulations and Community legislation or provisions issued by legally empowered authorities and vigilance and control bodies, and to perform our business activities and fulfil our accounting, taxation and corporate organisational obligations, we are not required to obtain your consent and failure to provide such data will make it impossible to continue the relationship to the extent that said data are necessary for performance of the same.

The purchase of products and services marketed by AVEC SRL enables the latter to forward informative, advertising and promotional material relating to its sector of expertise in compliance with the methods indicated in point 1), pursuant to point 6 of the provision 'Simplification of certain requirements in the public and private domain concerning data processing for administrative and accounting purposes' - 19 June 2008 Gazzetta Ufficiale (Official Bulletin) no. 152 dated 1 July 2008. Should you decide to object to the processing operations for commercial purposes, said refusal/objection will not have any consequences of any kind. The providing of personal data in order to receive advertising and informative material relating to our area of expertise either in printed form or electronically is entirely optional. Should you decide to object to the processing operations for commercial purposes, said refusal/objection will not have any consequences of any kind.

3) The personal data are processed by the persons in charge who are assigned to said processing in order to ensure correct fulfilment of the purposes indicated in point 1) via electronic instruments and printed files, also via use of safety measures aimed at guaranteeing the confidentiality of the personal data and preventing undue access by unauthorised subjects. Said data will not be subject to disclosure.

Data may be disclosed to the following subjects in their capacity as autonomous data processing controllers and/or in charge of external processing:

- accountants for bookkeeping and taxation obligations;
- attorneys for legal assistance for contractual purposes and management of litigation;
- entities/companies which collaborate with our company in the various sectors, for reasons strictly connected to the purposes set forth in point 1;
- banks and credit institutions.

You may contact the processing controller and persons in charge in order to exercise your rights as set forth in article 7 of Legislative Decree no. 196/2003, that is, the confirmation of the existence or otherwise of the data concerning you, the erasure, anonymization and blocking of data that has been processed unlawfully, the updating, rectifying or integrating of data, certification to the effect that the operations have been notified to the entities to whom or which said data were communicated or disseminated. The right to object to the processing of personal data for the commercial purposes set forth in point 1 d), where it is carried out via automated contact means, shall also be extended to traditional means without prejudice to the possibility for the interested party to exercise this right in part, pursuant to art. 7, subsection 4, letter b), of the Code, that is, by only objecting for example to the sending of promotional communications with the help of automated means. All requests may be forwarded by email to: info@avec-eventi.com by phone to: 0362/581579, or by fax to 0362/186074.

4) The data controller is: AVEC SRL Via Lavoratori, Autobianchi, 1 - Lotto 9/Uff.14 - 20832 – Desio(MB)

5) The person in charge of the processing is: Volpe Angela

The purchase of products and services marketed by AVEC SRL enables the latter to forward informative, advertising and promotional material relating to its sector of expertise, as set forth in point 1), by email or in printed form and also by means of automated systems, pursuant to point 6 provision 'Simplification of certain requirements in the public and private domain concerning data processing for administrative and accounting purposes' - 19 June 2008 Gazzetta Ufficiale (Official Bulletin) no. 152 dated 1 July 2008.
If you do not wish to receive such material mark a cross in the box alongside and send this informative note back to us by email or fax duly signed and stamped. The interested party’s right to object to the processing of personal data for the commercial purposes set forth in point 1 d), where it is carried out via automated contact means, shall also be extended to traditional means without prejudice to the possibility for the interested party to exercise this right in part, pursuant to art. 7, subsection 4, letter b), of the Code, that is, for example by only objecting to the sending of promotional communications with the help of automated means. Therefore, in the case of any objections, we invite you to specify in detail*, whether you intend to totally object to the purposes in 1/e, or only to some of the methods (e.g. objection to sending by fax or email etc.). In case of a general objection then you will not be contacted personally, telephonically or by email in relation to the promotional activities and initiatives proposed by the company.

I have read the above data protection notice and I agree with its terms.

Date:___________________________________

Signature for acceptance_________________________________
BERTONI Francesco
Head, Lymphoma & Genomics Research Program
Vice-director, IOR Institute of Oncology Research
Fondazione per la Ricerca e la Cura dei Linfomi nel Ticino
Lymphoma Unit, IOSI Oncology Institute of Southern Switzerland
Editor-in-Chief, Hematological Oncology
Vice-president, SAKK Project Group Lymphoma
Bellinzona (Switzerland)

BURGER Jan
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston (United States of America)

CALIGARIS-CAPPIO Federico
Professor of Medicine
Scientific Director AIRC
Milan (Italy)

CAMPO Elias
Hematopathology Unit
Hospital Clinic
Barcelona (Spain)

CHIORAZZI Nicholas
The Feinstein Institute for Medical Research
Manhasset (United States of America)

CROCE Carlo M.
The Ohio State University
Columbus, OH (United States of America)

DALLA FAVERA Riccardo
Institute for Cancer Genetics
Columbia University
New York (United States of America)

DE PAOLI Paolo
Oncology Reference Center (CRO) - IRCCS
National Cancer Institute
Aviano (Italy)
DEAGLIO Silvia
Associate Professor of Medical Genetics
University of Turin, School of Medicine & Italian Institute for Genomic Medicine
Turin (Italy)

DEL POETA Giovanni
Associate Professor of Blood Diseases
Chair of Hematology
DH Oncohematology
University Tor Vergata
Rome (Italy)

DI RAIMONDO Francesco
Division of Hematology
AOUP Vittorio Emanuele
University of Catania
Catania (Italy)

DREGER Peter
Medical Clinic V
University Clinic
Heidelberg (Germany)

EFREMOV Dimitar G.
Molecular Hematology Unit
International Center for Genetic Engineering and Biotechnology
Trieste (Italy)

EICHORST Barbara
University Hospital Cologne
Cologne (Germany)

FERRAJOLI Alessandra
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston (United States of America)

FOA’ Robin
Professor of Hematology
Head, Division of Hematology
University "Sapienza"
Rome (Italy)

FORCONI Francesco
Associate Professor in Haematological Oncology
Honorary Consultant in Haematology
Southampton (United Kingdom)
GAIDANO Gianluca  
Professor of Hematology  
Director, Division of Hematology  
Department of Translational Medicine  
University of Eastern Piedmont  
Novara (Italy)  

GATTEI Valter  
Head Clinical and Experimental Onco-Hematology Unit  
Centro di Riferimento Oncologico, I.R.C.C.S.  
Aviano (Italy)  

GHIA Paolo  
University Vita-Salute San Raffaele and IRCCS Scientific Institute San Raffaele  
Milan (Italy)  

GRIBBEN John  
Chair of Medical Oncology  
Barts Cancer Institute - a CR-UK Centre of Excellence  
Queen Mary University of London  
London (United Kingdom)  

HARTMANN Tanja  
Third Medical Department, Paracelsus Medical University  
Salzburg (Austria)  

JUMAA Hassan  
Institute of Immunology  
University Hospital Ulm  
Ulm (Germany)  

KAY Neil  
Professor of Medicine  
Department of Internal Medicine, Division of Hematology  
Mayo Clinic  
Rochester (United States of America)  

LAURENTI Luca  
UOC Ematologia  
Fondazione Policlinico Gemelli - Università Cattolica del Sacro Cuore  
Rome (Italy)
MARASCA Roberto
Department of Medical and Surgical Sciences, Section of Hematology
University of Modena and Reggio E.
AOU Polyclinic
Modena (Italy)

MASSAIA Massimo
Department of Molecular Biotechnology and Health Science
School of Medicine
University of Turin
Turin (Italy)

MONTILLO Marco
Department of Haematology & Oncology
Service of Haematology
Director of Chronic Lymphoproliferative Disorders Program
Niguarda Cancer Center - Niguarda Hospital
Milano (Italy)

MONTSERRAT Emili
Department of Hematology
Clinical Institute of Hemato-Oncological Diseases
Barcelona (Spain)

PIZZOLO Giovanni
University of Verona
Verona (Italy)

POZZATO Gabriele
Clinical Ematology
Maggiore Hospital
Trieste (Italy)

ROSENQUIST Richard
Department of Immunology, Genetics and Pathology
Uppsala University
Uppsala (Sweden)

ROSSI Davide
Hematology Service IOSI Institute of Oncology of the Italian Switzerland
Lymphoma & Genomics Research Program IOR Institute of Oncology Research
Bellinzona (Switzerland)

SHPALL Elizabeth
Cell Therapy Laboratory
Department of Stem Cell Transplantation - Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center,
Houston (United States of America)
SPINA Michele  
Division of Medical Oncology  
National Cancer Institute  
Aviano (Italy)

STAMATOPoulos Kostas  
Institute of applied Biosciences  
Center for Research and Technology Hellas  
Thessaloniki (Greece)

Trentin Livio  
Associate Professor of Hematology  
Division of Hematology  
Department of Medicine  
University of Padua  
Padua (Italy)

Wierda William G.  
Department of Leukemia  
Division of Cancer Medicine  
The University of Texas MD Anderson Cancer Center  
Houston (United States of America)

Wiestner Adrian  
Lymphoid Malignancies Section  
Hematology Branch  
National Heart, Lung and Blood Institute NHLBI – National Institutes of Health NIH  
Bethesda (United States of America)

Wu Catherine  
Associated researcher and institute member - Broad Institute’s Cancer Program  
Associate professor of medicine - Harvard Medical School and Dana-Farber Cancer Institute (DFCI)  
Staff physician – Dana-Farber Cancer Institute (DFCI) and Brigham and Women’s Hospital  
Boston (United States of America)

Zaja Francesco  
Hematology Clinic  
Udine Integrated Healthcare Company  
Udine (Italy)

Zucchetto Antonella  
Oncology Reference Center  
Aviano (Italy)